A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 May 2012

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2012 Results presented at the 31st Annual Scientific Meeting of the American Pain Society.
    • 21 Dec 2011 Last checked against ClinicalTrials.gov record.
    • 09 Nov 2011 Health outcomes results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top